Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Alto Neuroscience, Inc. (ANRO)

Tipranks - Tipranks - Fri Apr 3, 8:02AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Boston Scientific (BSX) and Alto Neuroscience, Inc. (ANRO) with bullish sentiments.

End of Quarter Sale - 50% Off TipRanks

Boston Scientific (BSX)

In a report released today, Matthew Taylor from Jefferies maintained a Buy rating on Boston Scientific, with a price target of $110.00. The company’s shares closed last Wednesday at $62.00.

According to TipRanks.com, Taylor is a 4-star analyst with an average return of 6.9% and a 54.2% success rate. Taylor covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Edwards Lifesciences, and Baxter International. ;'>

Boston Scientific has an analyst consensus of Strong Buy, with a price target consensus of $103.95, representing a 63.1% upside. In a report issued on March 30, TipRanks – PerPlexity also upgraded the stock to Buy with a $77.00 price target.

See today’s best-performing stocks on TipRanks >>

Alto Neuroscience, Inc. (ANRO)

Jefferies analyst Andrew Tsai maintained a Buy rating on Alto Neuroscience, Inc. today and set a price target of $35.00. The company’s shares closed last Wednesday at $23.41.

According to TipRanks.com, Tsai is a 5-star analyst with an average return of 25.7% and a 58.0% success rate. Tsai covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Definium Therapeutics, and Sarepta Therapeutics. ;'>

Currently, the analyst consensus on Alto Neuroscience, Inc. is a Strong Buy with an average price target of $34.88, implying a 54.5% upside from current levels. In a report issued on March 18, Stifel Nicolaus also maintained a Buy rating on the stock with a $33.00 price target.

Read More on BSX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).